Neonode Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Neonode Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $3.11M | Mar 21, 2025 |
| FY2024 | Dec 31, 2023 | $3.83M | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | $5.67M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $5.84M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $5.98M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $6.65M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $8.54M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $10.24M | Mar 7, 2019 |
| FY2016 | Dec 31, 2016 | $2.87M | Mar 15, 2017 |
| FY2016 | Sep 30, 2016 | $1.64M | Mar 15, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.04M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $2.99M | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $3.82M | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | $4.87M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $4.88M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $4.91M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $5.96M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $7.62M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $7.90M | Mar 7, 2019 |
| FY2016 | Dec 31, 2016 | $2.54M | Mar 15, 2017 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.49M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | ($6.47M) | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | ($10.12M) | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | ($4.88M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | ($6.45M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($6.28M) | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | ($5.30M) | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | ($3.06M) | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | ($4.71M) | Mar 7, 2019 |
| FY2016 | Dec 31, 2016 | ($431.0K) | Mar 15, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.37M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | ($6.55M) | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | ($5.74M) | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | ($5.29M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | ($7.11M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($6.19M) | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | ($5.73M) | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | ($3.88M) | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | ($5.48M) | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | ($5.14M) | Mar 8, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.78M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $3.44M | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $3.83M | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | $3.96M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $3.55M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $4.14M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $5.24M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $5.28M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $6.08M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | $7.07M | Mar 8, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $1.30M | Mar 21, 2025 |
| FY2024 | Dec 31, 2023 | $1.48M | Mar 21, 2025 |
| FY2022 | Dec 31, 2022 | $35.0K | Mar 9, 2023 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($10.25M) | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | ($5.59M) | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | ($6.31M) | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | ($6.81M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | ($7.68M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($5.75M) | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | ($3.52M) | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | ($2.86M) | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | ($5.58M) | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | ($6.25M) | Mar 8, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $91.0K | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $37.0K | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $123.0K | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | $52.0K | Feb 28, 2024 |
| FY2020 | Dec 31, 2020 | $60.0K | Mar 10, 2021 |
| FY2020 | Dec 31, 2019 | $89.0K | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $236.0K | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $656.0K | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | $987.0K | Mar 8, 2018 |
| FY2017 | Dec 31, 2015 | $198.0K | Mar 8, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $26.89M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $18.38M | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $19.01M | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | $21.20M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $22.99M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $16.57M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $7.44M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $13.24M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $13.13M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | $9.70M | Mar 8, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.20M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $1.94M | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $1.85M | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | $1.78M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $3.16M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $4.68M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $3.59M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $3.45M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $5.26M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | $5.57M | Mar 8, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.69M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $16.44M | Mar 18, 2026 |
| FY2025 | Dec 31, 2023 | $17.16M | Mar 18, 2026 |
| FY2023 | Dec 31, 2022 | $19.42M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $23.88M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $15.11M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $6.39M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $11.84M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $9.02M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | $4.51M | Mar 8, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($215.59M) | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | ($224.08M) | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | ($217.61M) | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | ($207.49M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | ($202.61M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($196.16M) | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | ($190.52M) | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | ($185.22M) | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | ($183.75M) | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | ($179.04M) | Mar 8, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $25.36M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $16.43M | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $16.16M | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | $14.82M | Feb 28, 2024 |
| FY2020 | Dec 31, 2020 | $10.47M | Mar 10, 2021 |
| FY2020 | Dec 31, 2019 | $2.36M | Mar 10, 2021 |
| FY2020 | Dec 31, 2018 | $6.56M | Mar 10, 2021 |
| FY2019 | Dec 31, 2017 | $5.80M | Mar 11, 2020 |
| FY2018 | Dec 31, 2016 | $3.48M | Mar 7, 2019 |
| FY2017 | Dec 31, 2015 | $3.08M | Mar 8, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 9, 2023 |
| FY2011 | Dec 31, 2011 | 0 | Mar 30, 2012 |
| FY2011 | Dec 31, 2010 | (1) | Mar 30, 2012 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 0 | Mar 21, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 9, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 16.78M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | 16.78M | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | 15.36M | Mar 21, 2025 |
| FY2023 | Dec 31, 2022 | 14.46M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | 13.58M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | 11.50M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | 9.17M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | 8.80M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | 5.86M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | 48.84M | Mar 8, 2018 |